Kancera AB (KAN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Kancera AB (KAN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8202
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kancera AB (Kancera) is a developer of drug candidates for the treatment of cancer. The company’s pipeline products include fractalkine inhibitor AZD8797, used to stop tumor growth; small molecule HDAC6 inhibitors, for neutralizing blood cancer; small molecule PFKFB3 inhibitors, for stopping energy supply from glucose to solid tumors; small molecule ROR inhibitors, for to reprogram cancer cells to destroy themselves, and small molecule inhibitors of epigenetic processes in parasites for developing new treatments to malaria and schistosomiasis. It caters to pharmaceutical and biotechnology companies. The company operates through its facility located in Stockholm, Sweden. Kancera is headquartered in Stockholm, Sweden.

Kancera AB (KAN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Kancera AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kancera AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kancera AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kancera AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Kancera AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Kancera AB, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Kancera Acquires Fractalkine Project from Acturum 10
Partnerships 11
Kancera and Recipharm Enter into Partnership 11
Kancera Enters into Co-Development Agreement with Acturum Life Science 12
Equity Offering 13
Kancera to Raise USD6.4 Million in Rights Offering of Units 13
Kancera Raises USD1.4 Million in Rights offering of Shares 14
Kancera AB – Key Competitors 15
Kancera AB – Key Employees 16
Kancera AB – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Financial Announcements 18
Jun 07, 2018: Interim-report for Kancera 1st January – 31st March 2018 18
Aug 23, 2017: Interim Report for Kancera for January 1st – June 30th 2017 20
Aug 22, 2017: Kancera Announces Its Interim Report Q2 2017 21
Feb 21, 2017: Interim Report for Kancera Q4 2016. January 1St – December 31St 2016 23
Other Significant Developments 25
Feb 21, 2017: Kancera Provides Operational Update Of The Project Portfolio 25
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
Kancera AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Kancera AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kancera AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kancera AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kancera AB, Deals By Therapy Area, 2012 to YTD 2018 8
Kancera AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Kancera Acquires Fractalkine Project from Acturum 10
Kancera and Recipharm Enter into Partnership 11
Kancera Enters into Co-Development Agreement with Acturum Life Science 12
Kancera to Raise USD6.4 Million in Rights Offering of Units 13
Kancera Raises USD1.4 Million in Rights offering of Shares 14
Kancera AB, Key Competitors 15
Kancera AB, Key Employees 16
Kancera AB, Subsidiaries 17

List of Figures
Kancera AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Kancera AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Kancera AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Kancera AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Kancera AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kancera AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Kancera AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kancera AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Kancera AB (KAN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bruce Power LP:企業の戦略的SWOT分析
    Bruce Power LP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Besso Insurance Group Limited:企業の戦略・SWOT・財務情報
    Besso Insurance Group Limited - Strategy, SWOT and Corporate Finance Report Summary Besso Insurance Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Conco, Inc.:企業の戦略・SWOT・財務情報
    Conco, Inc. - Strategy, SWOT and Corporate Finance Report Summary Conco, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • World Reach Limited (WRR):企業の財務・戦略的SWOT分析
    World Reach Limited (WRR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Women’s Choice Pharmaceuticals LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Women's Choice Pharmaceuticals LLC (WCP) is a pharmaceutical company that offers prescription products for women’s health care and urology markets. The company’s products include fem pH, a therapeutic vaginal jelly that is used to promote and maintain vaginal acidity caused by diabetes, horm …
  • Otrum AS:企業の戦略的SWOT分析
    Otrum AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Greer Laboratories Inc-製薬・医療分野:企業M&A・提携分析
    Summary Greer Laboratories Inc (Greer), a subsidiary of Stallergenes Greer plc, is a pharmaceutical company that provides allergy immunotherapy products and services to the healthcare industry. The company provides products in the area of human allergy, veterinary allergy and source materials. It of …
  • Shearman & Sterling LLP:企業の戦略的SWOT分析
    Shearman & Sterling LLP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • WellCare Health Plans Inc (WCG):製薬・医療:M&Aディール及び事業提携情報
    Summary WellCare Health Plans Inc (WellCare) is a managed care services provider which focuses on providing government-sponsored managed care services to families, children, seniors and individuals with complex medical needs. The company offers Medicaid health plans, Medicare Advantage (MA) coordina …
  • Materialise NV (MTLS):企業の財務・戦略的SWOT分析
    Materialise NV (MTLS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Copalis:戦略・SWOT・企業財務分析
    Copalis - Strategy, SWOT and Corporate Finance Report Summary Copalis - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • UGI Corp (UGI):企業の財務・戦略的SWOT分析
    UGI Corp (UGI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Emirates Flight Catering:企業の戦略・SWOT・財務分析
    Emirates Flight Catering - Strategy, SWOT and Corporate Finance Report Summary Emirates Flight Catering - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Michael Foods, Inc.:企業の戦略・SWOT・財務情報
    Michael Foods, Inc. - Strategy, SWOT and Corporate Finance Report Summary Michael Foods, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • China Mengniu Dairy Co Ltd:企業のM&A・事業提携・投資動向
    China Mengniu Dairy Co Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's China Mengniu Dairy Co Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Henry Schein, Inc.:企業の戦略・SWOT・財務情報
    Henry Schein, Inc. - Strategy, SWOT and Corporate Finance Report Summary Henry Schein, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Gene Techno Science Co Ltd (4584):製薬・医療:M&Aディール及び事業提携情報
    Summary Gene Techno Science Co Ltd (GTS) is a developer and marketer of drug and antibodies for intractable diseases, cancer, and rare diseases. The company develops biological and biosimilar products. Its biological pipeline products include GND-004, for oncology; GND-001 for immunological disease …
  • Boule Diagnostics AB (BOUL):医療機器:M&Aディール及び事業提携情報
    Summary Boule Diagnostics AB (Boule) is a medical device company that offers hematology diagnostic solutions. The company provides systems and consumer products for complete blood counts to non-institutional healthcare. It offers products such as blood cell counter and instruments, reagents, calibra …
  • Ocular Therapeutix Inc (OCUL):企業の財務・戦略的SWOT分析
    Summary Ocular Therapeutix Inc (Ocular), formerly I-Therapeutix Inc is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for diseases using hydrogel platform technology. The company’s products include DEXTENZA, sustained release travoprost and posterior …
  • The Hershey Co:企業のM&A・事業提携・投資動向
    The Hershey Co - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Hershey Co Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆